Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[55Co]Co-DOTA-hEGF
- Development stage
- Preclinical
- Lead developer
- Odense Universitetshospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Implant
01
Overview
[55Co]Co-DOTA-hEGF is a radiopharmaceutical diagnostic agent designed for positron emission tomography (PET) imaging. It consists of human epidermal growth factor (hEGF) conjugated to the macrocyclic chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and labeled with the radioisotope cobalt-55 (55Co). The hEGF moiety specifically targets the epidermal growth factor receptor (EGFR), which is frequently overexpressed in glioblastoma multiforme (GBM). This tracer is primarily utilized in the context of convection-enhanced delivery (CED), a technique that bypasses the blood-brain barrier to deliver therapeutics directly into the brain parenchyma. By using [55Co]Co-DOTA-hEGF with dynamic PET/MRI, researchers can visualize drug distribution, calculate volume of distribution (Vd) to infusion volume (Vi) ratios, and optimize catheter placement for improved therapeutic efficacy in brain tumor patients.
- Other names
- 55Co-DOTA-hEGFCobalt-55 labeled DOTA-hEGFCobalt55 labeled DOTA-hEGFCobalt 55 labeled DOTA-hEGF
02
Targets
Beyond the preview
Go deeper on [55Co]Co-DOTA-hEGF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [55Co]Co-DOTA-hEGF.